Evolus (NASDAQ:EOLS) Downgraded by Mizuho

Mizuho lowered shares of Evolus (NASDAQ:EOLS) from a buy rating to a neutral rating in a report released on Tuesday morning, AnalystRatings.com reports. Mizuho currently has $3.00 target price on the stock, down from their previous target price of $8.00.

Several other equities analysts have also weighed in on EOLS. HC Wainwright reduced their price target on shares of Evolus from $15.00 to $7.00 and set a buy rating for the company in a research report on Tuesday. SunTrust Banks lowered their price target on shares of Evolus from $18.00 to $12.00 and set a buy rating on the stock in a report on Tuesday, May 12th. Wells Fargo & Co reduced their price objective on Evolus from $10.00 to $5.00 and set an equal weight rating for the company in a report on Thursday, April 30th. SVB Leerink decreased their target price on Evolus from $25.00 to $15.00 and set an outperform rating for the company in a research report on Friday, April 3rd. Finally, Barclays dropped their price target on Evolus from $9.00 to $4.00 and set an underweight rating on the stock in a research report on Wednesday, May 13th. Two analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $11.88.

EOLS stock opened at $3.03 on Tuesday. The company has a quick ratio of 5.02, a current ratio of 5.58 and a debt-to-equity ratio of 1.24. The firm has a market cap of $112.99 million, a PE ratio of -0.89 and a beta of 3.19. The business has a 50 day moving average of $5.05 and a 200-day moving average of $6.86. Evolus has a 12-month low of $3.00 and a 12-month high of $20.27.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.03). Evolus had a negative return on equity of 197.30% and a negative net margin of 217.51%. The business had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $16.91 million. On average, research analysts expect that Evolus will post -2.58 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its holdings in shares of Evolus by 209.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,776 shares of the company’s stock worth $28,000 after acquiring an additional 4,583 shares during the period. Royal Bank of Canada lifted its holdings in Evolus by 55.6% during the 1st quarter. Royal Bank of Canada now owns 7,141 shares of the company’s stock worth $30,000 after purchasing an additional 2,553 shares in the last quarter. Edge Wealth Management LLC boosted its stake in Evolus by 325.0% in the 1st quarter. Edge Wealth Management LLC now owns 8,500 shares of the company’s stock worth $36,000 after purchasing an additional 6,500 shares during the period. Ironwood Investment Counsel LLC bought a new position in Evolus in the 1st quarter worth about $42,000. Finally, JNB Advisors LLC purchased a new position in Evolus during the 1st quarter valued at about $46,000. Hedge funds and other institutional investors own 42.43% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Article: What is the NASDAQ?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.